| Lincare Inc | |
| 709 City Center Blvd, Ste A107, Newport News, Virginia 23606 | |
| (757) 566-9624 |
| Name | Lincare Inc |
|---|---|
| Organization Name | Lincare Inc |
| Location | 709 City Center Blvd, Ste A107, Newport News, Virginia 23606 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (757) 566-9624 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The researchers reported the results of a meta-analysis of 68 chemotherapy trials for cancer treatment between 2000 and 2006 - before the gradual introduction of targeted cancer therapies (drugs that target specific molecular pathways in tumour cells) from 2007, which today can be prescribed alongside cytotoxic drugs.
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.
Researchers have found a more accurate way to tell which children and teenagers are likely to be among the thousand or so who suddenly die each year in the United States from genetic heart conditions that cause arrhythmia
› Verified 2 days ago
| NPI Number | 1013947761 |
| Organization Name | LINCARE INC. |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 709 City Center Blvd Ste A107, Newport News, VA 23606 |
| Phone Number | 757-566-9624 |
News Archive
The researchers reported the results of a meta-analysis of 68 chemotherapy trials for cancer treatment between 2000 and 2006 - before the gradual introduction of targeted cancer therapies (drugs that target specific molecular pathways in tumour cells) from 2007, which today can be prescribed alongside cytotoxic drugs.
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.
Researchers have found a more accurate way to tell which children and teenagers are likely to be among the thousand or so who suddenly die each year in the United States from genetic heart conditions that cause arrhythmia
› Verified 2 days ago
News Archive
The researchers reported the results of a meta-analysis of 68 chemotherapy trials for cancer treatment between 2000 and 2006 - before the gradual introduction of targeted cancer therapies (drugs that target specific molecular pathways in tumour cells) from 2007, which today can be prescribed alongside cytotoxic drugs.
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.
Researchers have found a more accurate way to tell which children and teenagers are likely to be among the thousand or so who suddenly die each year in the United States from genetic heart conditions that cause arrhythmia
› Verified 2 days ago
1st Choice In-homecare Inc Type: Medicare Supplier Location: 321 Ed Wright Right Lane Suite B-c, Newport News, Virginia 23606 Phone: (757) 496-2030 | |
Med Emporium #2 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 629 Pilot House Dr, Newport News, Virginia 23606 Phone: (757) 434-5777 | |
Care Plus Cvs/pharmacy #10922 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4500 Washington Ave, Newport News, Virginia 23607 Phone: (757) 928-0860 | |
Coastal Prosthetics And Orthotics L Type: Prosthetic/Orthotic Supplier Location: 11818 Rock Landing Dr, Newport News, Virginia 23606 Phone: (757) 240-4228 | |
Rite Aid Pharmacy 11285 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 13271 Warwick Blvd, Newport News, Virginia 23602 Phone: (757) 874-3047 |